Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 327 followers
Latest posts
Last updated about 7 hours ago
NIH imposes full ban of aborted fetal tissue in research
about 7 hours ago
The National Institutes of Health (NIH) has reinstated a ban on the...
Hoth strikes back against cancer drug skin toxicities, but share price stays frozen
about 11 hours ago
Hoth Therapeutics has shared phase 2 results on its treatment of EGFR...
Corxel secures $287M series D to fund phase 2/3 obesity studies of oral GLP-1 drug
about 12 hours ago
In a reminder of the money still available for enticing obesity assets...
Corcept racks up phase 3 cancer win to bounce back from FDA Cushing’s rejection
about 12 hours ago
Corcept Therapeutics’ relacorilant has improved overall survival in a phase 3 ovarian...
BMS pens $850M solid tumor pact with T-cell engager biotech Janux
about 13 hours ago
Bristol Myers Squibb will pay T-cell engager company Janux Therapeutics $50 million...
FDA outlines draft policy on MRD, complete response for accelerated approvals in multiple myeloma
1 day ago
After a short delay and concerns of potential intervention from senior officials...
Pfizer CEO lays blame for US vaccine woes on RFK Jr.'s 'anti-science' stance: WSJ
1 day ago
While much of the biopharma industry has spent the past 12 months...
Novo Nordisk offloads diabetes assets to Aspect amid cell therapy retreat
1 day ago
Novo Nordisk has found a buyer for cell therapy technologies dropped in...
Cancer imaging company buys Lisata for phase 2-stage solid tumor drug
1 day ago
Cancer imaging company Kuva Labs is expanding its scope via the acquisition...
Touching base: Beam CEO on gene editing biotech's 'big push' for in vivo delivery
1 day ago
Riding a regulatory win for its base editing candidate, Beam Therapeutics is...
IO mulls more layoffs months after halving head count in wake of cancer vaccine setback
1 day ago
Only four months after IO Biotech decided to halve its head count...
Insilico agrees on $66M deal to split rights for preclinical NLRP3 inhibitor with new Chinese biotech
1 day ago
AI-powered drug developer Insilico Medicine is set for a $10 million upfront...